VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
XCUR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
XCURExicure, Inc.
$1.90$12M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

XCUR logoExicure, Inc.(XCUR)Earnings, Financials & Key Ratios

XCUR•NASDAQ
$1.90
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryRNA and Genome Editing Developers
AboutExicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Show more
  • Revenue$0-100.0%
  • EBITDA-$10M+15.3%
  • Net Income-$5M+49.0%
  • EPS (Diluted)-0.79+50.3%
  • ROE-92.47%+53.3%

XCUR Price & Volume

Exicure, Inc. (XCUR) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Absence Signals Critical Liquidity Risk

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent Liquidity Exhaustion

Key Thesis Takeaways

  • Exicure faces a precarious outlook as it operates without any revenue generation, evidenced by multiple quarters of zero top-line growth.
  • The company's reliance on a non-productive cost structure, with quarterly operating expenses consistently exceeding $1.5 million, continues to erode its remaining $2.6 million cash balance.
  • Investors should remain cautious as the firm's inability to secure milestone-driven inflows or scale its operations suggests a high probability of further equity dilution or insolvency.

Verdict Logic

the company's rapid depletion of cash reserves to $2.6 million in 2026Q1, combined with a lack of revenue, suggests an imminent risk of liquidity exhaustion that outweighs potential upside.

XCUR Growth Metrics

Exicure, Inc. (XCUR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-66.91%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-67.5%

Return on Capital

10 Years-76.19%
5 Years-83.71%
3 Years-101.7%
Last Year-91.4%

XCUR Recent Earnings

Exicure, Inc. (XCUR) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 3/12 qtrs (100%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 29, 2026
Metric
Actual
Est
EPS
$0.29+98.4%
$18.60
Rev
—
$2M
Q2 2026
Mar 25, 2026
Metric
Actual
Est
EPS
$0.46+51.6%
$0.95
Rev
—
$4M
Q4 2025
Nov 7, 2025
Metric
Actual
Est
EPS
$0.39
—
Rev
—
—
Q3 2025
Aug 8, 2025
Metric
Actual
Est
EPS
$0.41
—
Rev
—
—
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 29, 2026
$0.29vs $18.60+98.4%
—vs $2M
Q2 2026Mar 25, 2026
$0.46vs $0.95+51.6%
—vs $4M
Q4 2025Nov 7, 2025
$0.39
—
Q3 2025Aug 8, 2025
$0.41
—
Based on last 12 quarters of dataView full earnings history →

Latest XCUR News

Recent stock market news and headlines for Exicure, Inc. (XCUR)

GlobeNewsWire·Jun 30, 2026
Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions approved by the Company's Board of Directors at its special meeting held on June 24, 2026.

Peers Comparison

Key metrics vs top competitors for Exicure, Inc. (XCUR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
XCUR logoXCURExicure, Inc.Current
$1.90$12.11M-2.41-100%—-92.47%—
SRPT logoSRPTSarepta Therapeutics, Inc.
$19.79$2.09B-2.7815.58%2.98%4.89%—
ARWR logoARWRArrowhead Pharmaceuticals, Inc.
$86.97$12.25B-7128.6923258.15%-48.38%-55.09%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$17.43$1.96B-4.5716.92%-597.04%-57.27%—
BEAM logoBEAMBeam Therapeutics Inc.
$37.92$3.9B-46.81120.01%-49.17%-5.89%—
EDIT logoEDITEditas Medicine, Inc.
$3.75$367.15M-2.0825.39%-281.59%-677.39%—

Compare XCUR vs Peers

Exicure, Inc. (XCUR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs SRPT

Most directly comparable listed peer for XCUR.

Scale Benchmark

vs TMO

Larger-name benchmark to compare XCUR against a more recognizable public peer.

Peer Set

Compare Top 5

vs SRPT, ARWR, NTLA, BEAM

XCUR SEC Filings & Documents

Exicure, Inc. (XCUR) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Jun 1, 2026·SEC

Material company update

Apr 10, 2026·SEC

Material company update

Apr 2, 2026·SEC

10-K Annual Reports

2
FY 2026

Mar 25, 2026·SEC

FY 2025

Mar 18, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 29, 2026·SEC

FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

Get notified when XCUR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

XCUR Frequently Asked Questions

Exicure, Inc. (XCUR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
How fast is Exicure, Inc. growing?

Exicure, Inc. (XCUR) saw revenue decline by 100.0% over the past year.

Is XCUR profitable?

Exicure, Inc. (XCUR) reported a net loss of $9.8M for fiscal year 2025.

Dividend & Returns
What is XCUR's return on equity?

Exicure, Inc. (XCUR) has a return on equity (ROE) of -92.5%. Negative ROE indicates the company is unprofitable.

What is Exicure, Inc.'s free cash flow?

Exicure, Inc. (XCUR) had negative free cash flow of $8.1M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in XCUR back in 2015?

Total return calculator · dividends reinvested · 11+ years of data

See returns →